Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Apply
Zanzalintinib, Durvalumab, Tremelimumab
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step